Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.
暂无分享,去创建一个
W. März | B. Boehm | B. Winkelmann | J. Hager | J. Senges | R. Zotz | J Hager | W März | P. Hellstern | B R Winkelmann | B O Boehm | R Zotz | P Hellstern | J Senges | Winfried März
[1] W. Kraus,et al. Genetics of coronary heart disease: current knowledge and research principles. , 2000, American heart journal.
[2] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[3] G. Specchia,et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. , 2000, European heart journal.
[4] P Glasziou,et al. Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.
[5] E. Braunwald,et al. A classification of unstable angina revisited. , 2000, Circulation.
[6] J P Ornato,et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. , 2000, JAMA.
[7] P. Grant,et al. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.
[8] B. Winkelmann,et al. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. , 2000, Pharmacogenomics.
[9] B. Gersh,et al. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. , 2000, Journal of the American College of Cardiology.
[10] N Reichek,et al. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. , 1999, Journal of the American College of Cardiology.
[11] A. Moss,et al. Q-wave versus non-Q wave myocardial infarction: a meaningless distinction. , 1999, Journal of the American College of Cardiology.
[12] L. S. Jónsdóttir,et al. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. , 1998, European heart journal.
[13] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[14] W D Flanders,et al. Sample size requirements in case-only designs to detect gene-environment interaction. , 1997, American journal of epidemiology.
[15] A. von Eckardstein,et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.
[16] R. D'Agostino,et al. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. , 1996, American journal of epidemiology.
[17] D G Altman,et al. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons , 1995, BMJ.
[18] G. Assmann,et al. Identification of individuals at high risk for myocardial infarction. , 1994, Atherosclerosis.
[19] H. Tunstall-Pedoe,et al. Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.
[20] L. Wilkins,et al. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.
[21] R. Klein,et al. Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.
[22] M. Woodward. Formulae for Sample Size, Power and Minimum Detectable Relative Risk in Medical Studies , 1992 .
[23] M. Scott,et al. New enzymatic CO2 slide on the Ektachem 700 XR analyzer eliminates interference from nitrate/nitrite ions. , 1992, Clinical chemistry.
[24] W. Little,et al. The underlying coronary lesion in myocardial infarction: Implications f coronary angiography , 1991, Clinical cardiology.
[25] C. Wanner,et al. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. , 1991, Kidney international.
[26] E. Braunwald,et al. Unstable angina. A classification. , 1989, Circulation.
[27] F. Harrell,et al. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. , 1986, The American journal of cardiology.
[28] W. Kannel,et al. Unrecognized myocardial infarction and hypertension: the Framingham Study. , 1985, American heart journal.
[29] L. Cupples,et al. Multiple testing of hypotheses in comparing two groups. , 1984, Annals of internal medicine.
[30] P. Hopkins,et al. A survey of 246 suggested coronary risk factors. , 1981, Atherosclerosis.
[31] J. Fleiss,et al. A simple approximation for calculating sample sizes for comparing independent proportions. , 1980, Biometrics.
[32] T. Kudo,et al. A greatly simplified method of establishing B-lymphoblastoid cell lines. , 1978, Cancer research.
[33] J. Tukey. Some thoughts on clinical trials, especially problems of multiplicity. , 1977, Science.
[34] L. Campeau. Letter: Grading of angina pectoris. , 1976, Circulation.
[35] J. Medalie,et al. Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. , 1976, Annals of internal medicine.
[36] W. Kannel,et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.